Published in World J Gastroenterol on July 28, 2006
The human microbiome and its potential importance to pediatrics. Pediatrics (2012) 1.74
Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis (2009) 0.88
Cellobiose Prevents the Development of Dextran Sulfate Sodium (DSS)-Induced Experimental Colitis. J Clin Biochem Nutr (2010) 0.82
Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease. World J Gastroenterol (2012) 0.82
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol (2016) 0.78
Flavanol-Enriched Cocoa Powder Alters the Intestinal Microbiota, Tissue and Fluid Metabolite Profiles, and Intestinal Gene Expression in Pigs. J Nutr (2016) 0.76
Anti-inflammatory effects of mannanase-hydrolyzed copra meal in a porcine model of colitis. J Vet Med Sci (2014) 0.75
Targeting intestinal microflora in inflammatory bowel disease. World J Gastroenterol (2006) 0.75
Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 29.32
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
Toll-like receptors. Annu Rev Immunol (2001) 26.06
Inflammatory bowel disease. N Engl J Med (2002) 21.17
Gut flora in health and disease. Lancet (2003) 9.85
Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology (1998) 9.58
CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science (2005) 8.97
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun (1998) 7.86
Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem (2000) 6.54
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 6.19
The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med (1994) 5.46
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (1999) 5.36
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25
Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut (2003) 5.19
Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology (2004) 5.19
Dysbiosis in inflammatory bowel disease. Gut (2004) 5.01
Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology (2001) 4.44
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun (1998) 3.80
How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol (2005) 3.40
Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol (1997) 3.05
MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol (2005) 3.02
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol (2002) 3.00
VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol (2005) 2.90
Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut (2003) 2.74
Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis (2006) 2.45
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut (1991) 2.24
NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem (2005) 2.06
Role of the faecal stream in the maintenance of Crohn's colitis. Gut (1985) 1.63
Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter (1998) 1.61
Micrococci and peptidoglycan activate TLR2-->MyD88-->IRAK-->TRAF-->NIK-->IKK-->NF-kappaB signal transduction pathway that induces transcription of interleukin-8. Infect Immun (2001) 1.59
Probiotic therapy of intestinal inflammation and infections. Curr Opin Gastroenterol (2005) 1.52
Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol (2003) 1.51
A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology (1982) 1.46
Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol (2006) 1.46
Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther (2004) 1.36
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol Immunol (2004) 1.34
Mechanism of pathogen-specific TLR4 activation in the mucosa: fimbriae, recognition receptors and adaptor protein selection. Eur J Immunol (2006) 1.32
Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol (2002) 1.30
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci (1999) 1.29
Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut (1985) 1.28
Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol (2000) 1.21
Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr Opin Gastroenterol (2005) 1.19
Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol (1999) 1.14
Role of dietary fiber and short-chain fatty acids in the colon. Curr Pharm Des (2003) 1.14
Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. Clin Exp Immunol (1999) 1.13
Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol (1994) 1.11
The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther (1990) 1.10
Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol (2001) 1.10
Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med (2001) 1.08
Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med (2004) 1.08
Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Dig Dis (2003) 1.07
Effects of germinated barley foodstuff on dextran sulfate sodium-induced colitis in rats. J Gastroenterol (1998) 1.06
Prebiotics and synbiotics: towards the next generation. Curr Opin Biotechnol (2002) 1.06
The intestinal flora in inflammatory bowel disease: normal or abnormal? Curr Opin Gastroenterol (2005) 1.06
Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb Technol (2000) 1.05
Ligand-receptor and receptor-receptor interactions act in concert to activate signaling in the Drosophila toll pathway. J Biol Chem (2005) 1.04
Host-bacterial interactions in inflammatory bowel disease. Clin Sci (Lond) (2004) 1.03
Alteration of V beta usage and cytokine production of CD4+ TCR beta beta homodimer T cells by elimination of Bacteroides vulgatus prevents colitis in TCR alpha-chain-deficient mice. J Immunol (2000) 0.99
Prebiotics and synbiotics in clinical medicine. Nutr Clin Pract (2005) 0.99
Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis. J Gastroenterol Hepatol (2001) 0.99
Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosaccharides. J Appl Microbiol (2001) 0.99
Microbial colonization drives lymphocyte accumulation and differentiation in the follicle-associated epithelium of Peyer's patches. J Immunol (2003) 0.98
Preventive effects of Bifidobacterium- and Lactobacillus-fermented milk on the development of inflammatory bowel disease in senescence-accelerated mouse P1/Yit strain mice. Digestion (2001) 0.97
Effect of dietary fibers on rat large bowel mucosal growth and cell proliferation. Am J Physiol (1984) 0.97
Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment Pharmacol Ther (1998) 0.97
Fiber, inulin and oligofructose: similarities and differences. J Nutr (1999) 0.95
Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med (2003) 0.95
The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr Pharm Des (2005) 0.95
Eubacterium limosum ameliorates experimental colitis and metabolite of microbe attenuates colonic inflammatory action with increase of mucosal integrity. World J Gastroenterol (2006) 0.94
Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol (1991) 0.94
Long-term ingestion of lactosucrose increases Bifidobacterium sp. in human fecal flora. Digestion (1995) 0.93
Germinated barley foodstuffs attenuate colonic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model. J Gastroenterol Hepatol (1999) 0.92
Inflammatory bowel disease requires the interplay between innate and adaptive immune signals. Cell Res (2006) 0.90
Augmentation of host defence against bacterial and fungal infections of mice pretreated with the non-pathogenic Escherichia coli strain Nissle 1917. Arzneimittelforschung (1997) 0.90
Microbial colonization induces oligoclonal expansions of intraepithelial CD8 T cells in the gut. Eur J Immunol (2004) 0.89
The dietary combination of germinated barley foodstuff plus Clostridium butyricum suppresses the dextran sulfate sodium-induced experimental colitis in rats. Scand J Gastroenterol (2000) 0.88
Pathogen-specific TLR signaling in mucosa: mutual contribution of microbial TLR agonists and virulence factors. Eur J Immunol (2006) 0.87
Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med (2002) 0.85
The metabolic activity of fecal microbiota from healthy individuals and patients with inflammatory bowel disease. Dig Dis Sci (2004) 0.85
Intestinal immunity of rats with colon cancer is modulated by oligofructose-enriched inulin combined with Lactobacillus rhamnosus and Bifidobacterium lactis. Br J Nutr (2004) 0.84
The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr Opin Gastroenterol (2005) 0.83
A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol (1989) 0.82
Effect of 4G-beta-D-galactosylsucrose (lactosucrose) on fecal microflora in patients with chronic inflammatory bowel disease. J Gastroenterol (1996) 0.81
Butyrate from bacterial fermentation of germinated barley foodstuff preserves intestinal barrier function in experimental colitis in the rat model. J Gastroenterol Hepatol (1999) 0.81
Synbiotics and the mucosal barrier in critically ill patients. Curr Opin Gastroenterol (2005) 0.80
Dietary psyllium increases fecal bile acid excretion, total steroid excretion and bile acid biosynthesis in rats. J Nutr (1998) 0.78
A case of Crohn's disease involving the gallbladder. World J Gastroenterol (2006) 0.77
Drug treatment of the irritable bowel syndrome. Drugs (1992) 0.76
Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology (2005) 3.65
Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol (2004) 3.41
Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol (2014) 2.30
Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol (2013) 1.80
IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol (2002) 1.64
Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol (2006) 1.59
Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol (2010) 1.58
Matrix metalloproteinase-3 secretion from human colonic subepithelial myofibroblasts: role of interleukin-17. J Gastroenterol (2003) 1.55
Interleukin-17 augments tumor necrosis factor-alpha-induced granulocyte and granulocyte/macrophage colony-stimulating factor release from human colonic myofibroblasts. J Gastroenterol (2005) 1.54
Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol (2003) 1.51
Butyrate blocks interferon-gamma-inducible protein-10 release in human intestinal subepithelial myofibroblasts. J Gastroenterol (2005) 1.49
Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol (2004) 1.46
Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol (2008) 1.43
Immunohistochemical analysis of cell cycle-regulating-protein (p21, p27, and Ki-67) expression in gastroesophageal reflux disease. J Gastroenterol (2002) 1.42
Luminal polyamines upregulate transmural glucose transport in the rat small intestine. J Gastroenterol (2002) 1.39
IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol (2002) 1.38
Novel biodegradable stents for benign esophageal strictures following endoscopic submucosal dissection. Dig Dis Sci (2007) 1.37
Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease. J Gastroenterol (2012) 1.31
Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol (2002) 1.30
Increased apoptosis and decreased proliferation of colonic epithelium in dextran sulfate sodium-induced colitis in mice. Oncol Rep (2010) 1.27
Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacol Ther (2007) 1.26
Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol (2011) 1.23
Usefulness of biodegradable stents constructed of poly-l-lactic acid monofilaments in patients with benign esophageal stenosis. World J Gastroenterol (2007) 1.22
Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol (2008) 1.19
The use of short-course zidovudine to prevent perinatal transmission of human immunodeficiency virus in rural Kenya. Am J Trop Med Hyg (2003) 1.16
Cross-sectional imaging in Crohn disease. Radiographics (2004) 1.15
Interleukin-32 expression in the pancreas. J Biol Chem (2009) 1.14
Role of dietary fiber and short-chain fatty acids in the colon. Curr Pharm Des (2003) 1.14
The S1P receptor modulator FTY720 prevents the development of experimental colitis in mice. Oncol Rep (2006) 1.13
Colonic subepithelial myofibroblasts in mucosal inflammation and repair: contribution of bone marrow-derived stem cells to the gut regenerative response. J Gastroenterol (2005) 1.12
Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping. J Gastroenterol Hepatol (2010) 1.09
Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis (2007) 1.09
Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med (2004) 1.08
Newly developed biodegradable stents for benign gastrointestinal tract stenoses: a preliminary clinical trial. Digestion (2007) 1.07
Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts. J Gastroenterol (2007) 1.07
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res (2008) 1.06
Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. Curr Pharm Des (2009) 1.06
IL-17 selectively down-regulates TNF-alpha-induced RANTES gene expression in human colonic subepithelial myofibroblasts. J Immunol (2002) 1.05
Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol (2003) 1.04
Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int J Mol Med (2006) 1.02
Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. Dig Dis Sci (2008) 1.02
Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural western Cameroon. J Acquir Immune Defic Syndr (2006) 1.00
The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol (2010) 1.00
Neutralization of complement component C5 ameliorates the development of dextran sulfate sodium (DSS)-colitis in mice. J Clin Biochem Nutr (2012) 0.99
Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease. J Gastroenterol (2013) 0.99
Energy metabolism in Japanese patients with Crohn's disease. J Clin Biochem Nutr (2009) 0.97
Interleukin-33 suppresses Notch ligand expression and prevents goblet cell depletion in dextran sulfate sodium-induced colitis. Int J Mol Med (2011) 0.97
Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-32alpha induction in human pancreatic periacinar myofibroblasts. Am J Physiol Gastrointest Liver Physiol (2008) 0.96
RANTES -28G delays and DC-SIGN - 139C enhances AIDS progression in HIV type 1-infected Japanese hemophiliacs. AIDS Res Hum Retroviruses (2007) 0.96
Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med (2003) 0.95
Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol (2005) 0.95
Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol (2011) 0.94
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol (2013) 0.94
Serum selenoprotein-P levels in patients with inflammatory bowel disease. Nutrition (2005) 0.94
Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol (2009) 0.94
Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma. Cancer Lett (2010) 0.93
Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease. Oncol Rep (2006) 0.93
Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease. J Gastroenterol (2004) 0.93
Bile acid modulates transepithelial permeability via the generation of reactive oxygen species in the Caco-2 cell line. Free Radic Biol Med (2005) 0.93
The free radical scavenger edaravone suppresses experimental dextran sulfate sodium-induced colitis in rats. Int J Mol Med (2003) 0.93
Hepatic reactive lymphoid hyperplasia in a patient with primary biliary cirrhosis. World J Hepatol (2010) 0.92
Cholangiocarcinoma in the distal bile duct: a probable etiologic association with choledocholithiasis. Dig Dis Sci (2005) 0.92
Energy expenditure in Japanese patients with severe or moderate ulcerative colitis. J Clin Biochem Nutr (2010) 0.92
Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut (2009) 0.92
OmpA variants affecting the adherence of ulcerative colitis-derived Bacteroides vulgatus. J Med Dent Sci (2010) 0.91
Lack of macrophage migration inhibitory factor suppresses innate immune response in murine dextran sulfate sodium-induced colitis. Scand J Gastroenterol (2008) 0.91
Collagenous gastritis in a young Japanese woman. Pathol Int (2003) 0.91
Hepatocellular carcinoma occurring in a Crohn's disease patient. World J Gastroenterol (2010) 0.91
Non-Epstein-Barr virus associated lymphoepithelioma-like carcinoma of the inferior common bile duct. World J Gastrointest Oncol (2011) 0.91
Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients. Mol Med Rep (2011) 0.91
New prebiotics from rice bran ameliorate inflammation in murine colitis models through the modulation of intestinal homeostasis and the mucosal immune system. Scand J Gastroenterol (2010) 0.90
Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. Dig Dis Sci (2007) 0.90
Enhancement of aquaporin-3 by vasoactive intestinal polypeptide in a human colonic epithelial cell line. J Gastroenterol Hepatol (2003) 0.89
A new therapeutic approach using a schizophyllan-based drug delivery system for inflammatory bowel disease. Mol Ther (2012) 0.89
Gastric inflammatory fibroid polyp treated with Helicobacter pylori eradication therapy. Intern Med (2003) 0.89
N-3 fatty acid-rich diet prevents early response of interleukin-6 elevation in trinitrobenzene sulfonic acid-induced enteritis. Int J Mol Med (2003) 0.89
Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J Biol Chem (2011) 0.88
Development of dextran sulfate sodium-induced colitis is aggravated in mice genetically deficient for complement C5. Int J Mol Med (2005) 0.88
Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial. Inflamm Bowel Dis (2010) 0.88
Suppression of inflammatory cytokine secretion by granulocyte/monocyte adsorptive apheresis in active ulcerative colitis. Ther Apher Dial (2005) 0.87
Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med (2007) 0.87
A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol (2002) 0.87
Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease. Intern Med (2008) 0.87
Interleukin 22 receptor 1 expression in pancreas islets. Pancreas (2008) 0.87
Clostridium butyricum, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. Int J Mol Med (2004) 0.87
Amphiregulin and epiregulin expression in neoplastic and inflammatory lesions in the colon. Oncol Rep (2008) 0.86
Alteration of aquaporin mRNA expression after small bowel resection in the rat residual ileum and colon. J Gastroenterol Hepatol (2003) 0.86
Usefulness of bispectral monitoring of conscious sedation during endoscopic mucosal dissection. World J Gastroenterol (2009) 0.85
Extracellular signal-regulated kinases 1 and 2 participate in interleukin-17 plus tumor necrosis factor-alpha-induced stabilization of interleukin-6 mRNA in human pancreatic myofibroblasts. Biochim Biophys Acta (2002) 0.85
Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med (2002) 0.85
Tacrolimus (FK506) suppresses TNF-α-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts. Int J Mol Med (2012) 0.85
Changes of energy metabolism, nutritional status and serum cytokine levels in patients with Crohn's disease after anti-tumor necrosis factor-α therapy. J Clin Biochem Nutr (2013) 0.84
Combined effect of hydrogen peroxide induced oxidative stress and IL-1 alpha on IL-8 production in CaCo-2 cells (a human colon carcinoma cell line) and normal intestinal epithelial cells. Inflammation (2003) 0.84
Interleukin-1beta and tumor necrosis factor-alpha upregulate interleukin-23 subunit p19 gene expression in human colonic subepithelial myofibroblasts. Int J Mol Med (2005) 0.84
Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis. J Gastroenterol Hepatol (2010) 0.84
Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells. Cancer Immunol Immunother (2001) 0.84
Dextran sulfate sodium administered orally is depolymerized in the stomach and induces cell cycle arrest plus apoptosis in the colon in early mouse colitis. Oncol Rep (2012) 0.83
Endoscopic submucosal dissection combined with the placement of biodegradable stents for recurrent esophageal cancer after chemoradiotherapy. J Gastrointest Cancer (2012) 0.83
Interleukin-32α expression in human colonic subepithelial myofibroblasts. Int J Mol Med (2010) 0.83